| PROMACTA (also known as eltrombopag) PROMACTA (eltrombopag) is an experimental oral platelet growth factor for treating idiopathic thrombocytopenia purpura (ITP). Patients with ITP have low number of platelets and they are prone to bleeding. This experimental drug stimulates the generation of platelets count by activating the thrombopoietin receptor on hematopoietic stem cells. A Phase 3 clinical study has shown that chronic ITP patients treated with PROMACTA had significantly higher platelet count and reduced bleeding than untreated patients. |
Plavix
Cardiovascularweb
 | |  | |  |
|
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |